In preclinical models, CSPG4-directed CAR T-cell therapy efficiently inhibits GBM-derived neurospheres growth in both in vitro, as well as in vivo xenograft patient-derived GBM orthotopic mouse model (156). The gene discussed is CSPG4; the disease is glioblastoma.